Key result
PDE10A inhibitors show enormous patent interest and potential for future clinical development.
Why the study?
The unique role of PDE10A and its increased pharmacological characterization have prompted interest in investigating PDE10A inhibitors as novel therapeutic agents.
Provides a comprehensive overview of recent patent activity regarding PDE10A inhibitors, highlighting their potential as novel therapeutic agents for psychiatric and neurodegenerative disorders.
PDE10A modulation merits cautious preclinical pursuit in psychiatric disorders; leaves open clinical translation pending targeted trials.
Phosphodiesterases are enzymes that metabolically inactivate the intracellular second messengers 3',5'-cyclic adenosine and guanosine monophosphate contributing to the control of multiple biological processes. Among them, PDE10A has the most restricted distribution with high expression in striatal medium spiny neurons. Dysfunction of this key brain circuit has been associated with different psychiatric and neurodegenerative disorders. The unique role of PDE10A, together with its increased pharmacological characterization, have prompted enormous interest in investigating the potential of inhibitors of this enzyme as potential novel therapeutic agents This article reviews PDE10A related patents issued in the period 2012-2014 in the USA and Europe offering also a perspective on potential avenues for the future clinical development of phosphodiesterase 10A inhibitors.
No takes yet. Share an insight, caveat, or question.
Bartolomé‐Nebreda et al. (2015) conducted a review in Psychiatric and neurodegenerative disorders. Phosphodiesterase 10A (PDE10A) inhibitors was evaluated. A review of US and European patents granted between 2012 and 2014 highlights the enormous interest and potential avenues for the future clinical development of phosphodiesterase 10A inhibitors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: